Superstring Capital Management
Latest statistics and disclosures from Superstring Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ORIC, TERN, ZLAB, NVCR, BBIO, and represent 44.92% of Superstring Capital Management's stock portfolio.
- Added to shares of these 10 stocks: COGT (+$7.1M), ORIC (+$6.7M), IDYA (+$5.8M), TERN, URGN, SMMT, PTGX, INSM, TARA, DYN.
- Started 20 new stock positions in LXEO, RZLT, ONC, DYN, KYTX, LSB, INSM, VSTM, EYPT, URGN. COGT, SMMT, IPSC, INCY, KURA, MDGL, TARA, IDYA, PTGX, AXSM.
- Reduced shares in these 10 stocks: ZLAB (-$8.5M), CYTK, CAPR, ETNB, NKTX, NVCR, ALLO, SYRE, BMEA, TRML.
- Sold out of its positions in SYRE, ALLO, BMEA, CRBP, CGEM, IMVT, NKTX, TRML, Ys Biopharma.
- Superstring Capital Management was a net buyer of stock by $18M.
- Superstring Capital Management has $116M in assets under management (AUM), dropping by 1.08%.
- Central Index Key (CIK): 0001931118
Tip: Access up to 7 years of quarterly data
Positions held by Superstring Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Superstring Capital Management
Superstring Capital Management holds 38 positions in its portfolio as reported in the December 2024 quarterly 13F filing
Company (Ticker) |
Portfolio Weight |
Valued At |
Change in Shares |
Share Count |
Share Price |
|
|---|---|---|---|---|---|---|
| Oric Pharmaceuticals Call Option (ORIC) | 12.4 | $14M | +87% | 1.8M | 8.07 |
|
| Terns Pharmaceuticals (TERN) | 9.7 | $11M | +49% | 2.0M | 5.54 |
|
| Zai Lab Adr (ZLAB) | 9.2 | $11M | -44% | 404k | 26.19 |
|
| Novocure Ord Shs (NVCR) | 7.4 | $8.6M | -26% | 287k | 29.80 |
|
| Bridgebio Pharma (BBIO) | 6.2 | $7.2M | +15% | 262k | 27.44 |
|
| Cogent Biosciences (COGT) | 6.2 | $7.1M | NEW | 911k | 7.80 |
|
| Cytokinetics Com New (CYTK) | 5.3 | $6.1M | -40% | 129k | 47.04 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 5.1 | $5.9M | -4% | 217k | 27.12 |
|
| Ideaya Biosciences (IDYA) | 5.1 | $5.8M | NEW | 227k | 25.70 |
|
| Urogen Pharma (URGN) | 2.8 | $3.2M | NEW | 301k | 10.65 |
|
| Summit Therapeutics (SMMT) | 2.5 | $2.9M | NEW | 165k | 17.84 |
|
| Instil Bio Com New (TIL) | 2.4 | $2.8M | +37% | 148k | 19.09 |
|
| Protagonist Therapeutics (PTGX) | 2.3 | $2.7M | NEW | 69k | 38.60 |
|
| Insmed Com Par $.01 (INSM) | 2.2 | $2.5M | NEW | 36k | 69.04 |
|
| Fate Therapeutics (FATE) | 2.0 | $2.3M | -5% | 1.4M | 1.65 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 2.0 | $2.3M | +15% | 70k | 32.54 |
|
| Protara Therapeutics Com Stk (TARA) | 1.6 | $1.9M | NEW | 360k | 5.28 |
|
| Cabaletta Bio (CABA) | 1.6 | $1.9M | +523% | 822k | 2.27 |
|
| Dyne Therapeutics (DYN) | 1.5 | $1.7M | NEW | 73k | 23.56 |
|
| Savara (SVRA) | 1.4 | $1.6M | +154% | 508k | 3.07 |
|
| Tango Therapeutics (TNGX) | 1.3 | $1.5M | -20% | 475k | 3.09 |
|
| Kura Oncology (KURA) | 1.2 | $1.4M | NEW | 158k | 8.71 |
|
| Incyte Corporation (INCY) | 1.1 | $1.2M | NEW | 18k | 69.07 |
|
| Beigene Sponsored Adr (ONC) | 1.0 | $1.2M | NEW | 6.4k | 184.71 |
|
| Verastem Com New (VSTM) | 0.9 | $1.1M | NEW | 210k | 5.17 |
|
| 89bio (ETNB) | 0.9 | $1.0M | -77% | 133k | 7.82 |
|
| Zenas Biopharma (ZBIO) | 0.8 | $914k | 112k | 8.19 |
|
|
| Capricor Therapeutics Com New (CAPR) | 0.7 | $762k | -83% | 55k | 13.80 |
|
| Kyverna Therapeutics (KYTX) | 0.6 | $681k | NEW | 182k | 3.74 |
|
| Rezolute Com New (RZLT) | 0.5 | $604k | NEW | 123k | 4.90 |
|
| Century Therapeutics (IPSC) | 0.4 | $468k | NEW | 463k | 1.01 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.4 | $467k | +19% | 187k | 2.50 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.3 | $368k | NEW | 49k | 7.45 |
|
| Axsome Therapeutics (AXSM) | 0.3 | $361k | NEW | 4.3k | 84.61 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.3 | $348k | NEW | 1.1k | 308.57 |
|
| Lexeo Therapeutics (LXEO) | 0.3 | $346k | NEW | 53k | 6.58 |
|
| Eliem Therapeutics (CLYM) | 0.2 | $177k | +190% | 98k | 1.80 |
|
| Lakeshore Biopharma Ord Shs New (LSB) | 0.1 | $106k | NEW | 31k | 3.45 |
|
Past Filings by Superstring Capital Management
SEC 13F filings are viewable for Superstring Capital Management going back to 2023
- Superstring Capital Management 2024 Q4 filed Feb. 14, 2025
- Superstring Capital Management 2024 Q3 filed Nov. 14, 2024
- Superstring Capital Management 2024 Q2 filed Aug. 14, 2024
- Superstring Capital Management 2024 Q1 filed May 15, 2024
- Superstring Capital Management 2023 Q4 filed Feb. 14, 2024